Clone of Centre for Amyloidosis

Information for patients on the coronavirus (COVID-19)

UPDATE:  As of 01 June 2020 the National Amyloidosis Centre has reopened. We will be conducting clinics via telephone/video-link, or where appropriate, in person. We will be in touch to let you know what type of appointment you will be having.

For FEVER PATIENTS who receive treatments at the Centre, such as Canakinumab, Anakinra and Tocilizumab, they will continue to have their appointments at this time.  Please contact Michael Wood or Bella Sombrito if you have any questions.

Information on coronavirus (COVID-19)

These teams undertake world leading, wide ranging, basic and clinical research on amyloid and amyloidosis, C‑reactive protein and serum amyloid A protein, leading to design and development of new treatments.

Head of Centre

Professor Julian Gillmore

Director of the Wolfson Drug Discovery Unit

Professor Sir Mark Pepys

Principal Investigators

• Professor Vittorio Bellotti
• Professor Marianna Fontana
• Professor Philip Hawkins
• Professor Helen Lachmann
• Dr Paul Simons
• Professor Ashutosh Wechalekar

The Centre for Amyloidosis is part of the Division of Medicine

• Information for Patients
• Information for Referring Physicians
• Histology and Proteomic Analysis
• Molecular Genetic Testing
• UK Amyloid Proteomics Facility